Companies /Healthcare
Guardant Health Inc
NASDAQ: GH Diagnostics & Research
$145.83
▲ $0.24 (+0.16%) today
Markets closed · 11:47pm ET

Guardant Health (GH) Q3 2026 Earnings

Reported Nov 5, 2026, 4:08pm ET · SEC source
$-0.29
Beat +7.76%
EPS · est. $-0.31 Adjusted

GAAP net loss includes $66.3 million of stock-based compensation and related payroll tax expense and $19.0 million of 'Other' items (e.g., contingent consideration and non-recurring legal expenses), both excluded from non-GAAP net loss; GAAP net loss per share was $0.93

$361.0M
Beat +2.95%
Revenue · est. $350.6M
1 quarter
Consecutive EPS beats

How Did GH Stock React to Q3 2026 Earnings?

% change · around the report
0+7%+14%+21%Nov 5Nov 6report 4:08pm ETearnings+0.5%+15.8%
0+7%+14%+21%Nov 5Nov 6earnings+0.5%+15.8%
GH +15.8%S&P 500 +0.5%
0+7%+14%+21%Nov 5Nov 6report 4:08pm ETearnings+1.5%+15.8%
0+7%+14%+21%Nov 5Nov 6earnings+1.5%+15.8%
GH +15.8%NASDAQ +1.5%
0+9%+18%+27%Nov 4Nov 12report 4:08pm ETearnings+3.7%+19.1%
0+9%+18%+27%Nov 4Nov 12earnings+3.7%+19.1%
GH +19.1%S&P 500 +3.7%
0+9%+18%+27%Nov 4Nov 12report 4:08pm ETearnings+6.8%+19.1%
0+9%+18%+27%Nov 4Nov 12earnings+6.8%+19.1%
GH +19.1%NASDAQ +6.8%
−1.67%
Day of report
+5.25%
Next session
+0.55%
One week

Did GH Beat Earnings? Q3 2026 Results

Yes. Guardant Health reported Q3 2026 earnings of $-0.29 a share on Nov 5, 2026, beating the $-0.31 consensus estimate by 7.8%. Revenue was $361.0M against a $350.6M estimate.

Guardant Health delivered a strong third quarter of fiscal 2026, beating analyst expectations on both the top and bottom lines as accelerating adoption of its Shield colorectal cancer screening test drove revenue 36.1% higher year over year to $360.98 million, ahead of the $350.64 million consensus. The adjusted loss per share of $0.29 came in 7.76% better than the $0.31 estimate, with the non-GAAP net loss narrowing to $38.80 million from $48.30 million a year earlier. The standout driver was the Screening segment, where revenue surged 180% to $67.60 million as Shield test volume reached 83,000, more than tripling from 24,000 a year ago; commercial coverage now extends to more than 80% of eligible lives, a figure set to grow further with recent policy expansions covering roughly 100 million lives. Oncology also contributed meaningfully, with revenue up 25% to $231.30 million on a 58% jump in test volume. Management raised its full-year 2026 revenue outlook to $1.36 billion to $1.37 billion, reflecting 38% to 40% growth, though it simultaneously widened free cash flow burn guidance to $205 million to $220 million, underscoring continued heavy investment in Shield commercialization.

Key Takeaways
  • Oncology test volume up 58% to 117,000 tests
  • Shield test volume up 246% to 83,000 tests
  • Non-GAAP gross margin improved to 67% from 66%
  • Biopharma & Data revenue growth of 8%

“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma.”

Guardant Health CEO, on the earnings call

What Is Guardant Health's Outlook?

Guardant raised its full-year 2026 outlook: - **Revenue:** $1.36–$1.37 billion (38%–40% growth vs. 2025), up from $1.34–$1.36 billion. - **Oncology:** revenue growth of approximately 30%, with volume growth now over 50%. - **Biopharma & Data:** revenue growth in the low double-digit range. - **Screening:** revenue now $233–$238 million on 285,000–290,000 Shield tests, up from $218–$230 million and 270,000–285,000 tests. - **Gross margin:** non-GAAP gross margin now 65%, vs. prior 64%–65%. - **Operating expenses:** non-GAAP operating expenses of $1.105–$1.125 billion, up from $1.080–$1.100 billion. - **Free cash flow:** burn now expected at $205–$220 million, vs. prior $195–$205 million.

GH YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$-200,000,000$0$200.0M$265.2M$361.0MRevenue$171.6M$236.2MGross Profit$-201,525,501$-132,765,000Operating Income$-188,770,492$-124,362,000Net Income
$-200,000,000$0$200.0MRevenueGross ProfitOperating IncomeNet Income
GH income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $361.0M $265.2M +36.1%
Gross Profit $236.2M $171.6M +37.6%
Operating Income −$132.8M −$201.5M −34.1%
Net Income −$124.4M −$188.8M −34.1%

GH Revenue by Segment

Oncology$231.3M+25.0%
Screening$67.6M+180.0%
Biopharma and Data$59.0M+8.0%
Licensing and Other$3.1M+60.2%

When Does Guardant Health Report Next?

Expected report date
After the close
Release timing

Figures from SEC filings and company reports. Not investment advice.